Company intelligence

KAPA

Kairos Pharma, Ltd. · AMEX · Healthcare

Price$1.65-1.79% · −$0.03

Market cap5.05MEquity value

P / E-5.9Trailing ratio

Volume75.89KLatest session

Market data

KAPA price chart

TradingView

Related signals

1 min delayed

Browse public KAPA signals with their source context and measured market impact. Open any signal for its permanent analysis page.

KAPAOct 6, 20260.00% since signal

Kairos Pharma's ENV-105 shows large PFS gain; watch Phase 2 progression to 2027

Kairos Pharma reported interim Phase 2 results showing ENV-105 combined with apalutamide significantly extended progression-free survival (PFS) versus apalutamide alone (17.7 months vs 2 months). The company also updated its protocol to enroll patients earlier in disease progression, aiming to broaden eligibility and finish the Phase 2 by 4Q2027, even as the stock trades near a 52-week low.

View signal analysis

KAPAJul 15, 2025+1.40% since signal

Why Is Kairos Pharma Stock Surging On Tuesday?

KAPA stock surged 57.64% on high volume of 221 million shares. Phase 2 trial of ENV-105 shows positive safety results in prostate cancer patients. No severe toxicities were reported, indicating favorable treatment tolerability. Kairos plans to engage regulators for a potential Phase 3 study. Interim efficacy data from the trial expected by September 2025.

View signal analysis

Research